Novartis Stock Analysis

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

USD 85.12  0.58  0.68%

Is it time to opt in on Novartis? Novartis Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The modest gains experienced by current holders of Novartis AG may encourage investors to take a closer look at the firm as it closed today at a share price of 84.94 on 1,801,116 in trading volume. The company directors and management have been quite successful with maneuvering the stock at opportune times to take advantage of all market conditions in May. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.71. The current volatility is consistent with the ongoing market swings in May 2020 as well as with Novartis AG unsystematic, company specific events. Additionally, see Stocks Correlation.

Search Stock Analysis

 
Refresh
The Novartis Stock analysis interface makes it easy to digest most current publicly released information about Novartis as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. Novartis stock analysis module also helps to analyze Novartis price relationship with some important fundamental indicators such as market cap and management efficiency.

Novartis Stock Analysis Notes

The book value of the company was now reported as 29.65. The company has Price/Earnings To Growth (PEG) ratio of 2.08. Novartis AG recorded earning per share (EPS) of 5.06. The entity last dividend was issued on 2020-03-03. The firm had 2:1 split on 2019-04-09. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 109000 people. To find out more about NOVARTIS AG ADS contact Chris Ilsley at 41 61 324 1111 or learn more at http://www.novartis.com.

Novartis AG Upcoming and Recent Events

Upcoming Quarterly Report16th of July 2020
Next Earnings Report27th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End3rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Anouncement30th of June 2019

Novartis Earnings Estimate

EPSEstimate Date
Quarterly Estimate1.4216th of July 2020
Novartis AG normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Novartis SEC Filings

Other Events
View
Other Events
View
Other Events
View
Other Events
View
Other Events
View
Other Events
View
Other Events
View
Other Events
View

Novartis Thematic Classifications

Drugs IdeaDrugs
Drug manufacturing and delivery
Healthcare IdeaHealthcare
USA Equities from Healthcare industry as classified by Fama & French
Compulsion IdeaCompulsion
Addiction driven consumer products and services

Market Capitalization

The company currently falls under 'Mega-Cap' category with total capitalization of 211.49 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of it shares issued and multiply it by the Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Profitablity

The company has Net Profit Margin of 0.25 % which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 33.89 % which entails that for every 100 dollars of revenue it generated 0.34 of operating income.

Management Efficiency

The entity has Return on Asset of 0.0821 % which means that on every $100 spent on asset it made $0.0821 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.1782 % implying that it generated $0.1782 on every 100 dollars invested. Novartis management efficiency ratios could be used to measure of how well novartis ag is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Novartis Return on Invested Capital is relatively stable at the moment as compared to the last year. Novartis reported last year Return on Invested Capital of 0.25. As of 06/05/2020, Return on Sales is likely to grow to 0.30, while Return on Average Assets are likely to drop 0.0008. Novartis Total Assets are relatively stable at the moment as compared to the last year. Novartis reported last year Total Assets of 118.37 Billion. As of 06/05/2020, Assets Non Current is likely to grow to about 102 B, while Asset Turnover is likely to drop 0.37. Novartis Total Liabilities is relatively stable at the moment as compared to the last year. Novartis reported last year Total Liabilities of 62.82 Billion. As of 06/05/2020, Liabilities Non Current is likely to grow to about 35.6 B, while Current Liabilities is likely to drop slightly above 23.7 B.

Technical Drivers

As of the 5th of June Novartis secures Downside Deviation of 2.94, Mean Deviation of 1.94 and Risk Adjusted Performance of 0.0895. In connection with Fundamental Indicators, Macroaxis technical analysis interface lets you check existing technical drivers of Novartis AG as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices or the prices will eventually revert. We found nineteen technical drivers for Novartis, which can be compared to its peers in the industry. Please verify Novartis AG Jensen Alpha and Semi Variance to decide if Novartis AG is priced some-what accurately providing market reflects its recent price of 85.12 per share. Given that Novartis AG has Jensen Alpha of 7.0E-4, we recommend you check Novartis last-minute market performance to make sure the company can sustain itself at future point.

Novartis AG Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Moving Average is predictive technique used to analyze Novartis AG price data points by creating a series of averages of different subsets of Novartis entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Novartis Predictive Indicators

Novartis Forecast Models

About Novartis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Novartis stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Novartis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Novartis. By using and applying Novartis Stock analysis, traders can create a robust methodology for identifying Novartis entry and exit points for their positions.
Last ReportedProjected for 2020
EBITDA Margin 0.29  0.30 
Gross Margin 0.70  0.66 
Profit Margin 0.24  0.0025 
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 109000 people.

Recommendations

Novartis AG Analyst Recommendations

Target PriceAdvice# of Analysts
104.33Buy3Odds
Novartis AG current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Novartis Analyst Advice  

Vital Value Indicators

Novartis Basic Pricing Drivers

Quick Ratio0.43
Fifty Two Week Low69.18
Trailing Annual Dividend Rate3.04
Revenue Growth10.90%
Payout Ratio95.58%
Shares Short Prior Month2.77M
Average Daily Volume Last 10 Day1.7M
Average Daily Volume In Three Month2.86M
Earnings Growth25.50%
Shares Percent Shares Out0.12%
Gross Margins71.09%
Earnings Quarterly Growth23.20%
Forward Price Earnings13.49
Float Shares2.14B
Fifty Two Week High99.84
Enterprise Value To Ebitda13.38
Fifty Day Average85.57
Two Hundred Day Average89.09
Trailing Annual Dividend Yield3.62%
Enterprise Value To Revenue4.53
Additionally, see Stocks Correlation. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page